

21st Austria ATX-Prime Stocks Week 49

| ATX TR | | | |
|--------------------------|--------|--------|---------|
| 3583.66 | 1.25% | 4.33% | |
| | Price | % week | % ytd |
| Addiko Bank | 19.45 | -0.26% | 45.69% |
| Aluflexpack | | | |
| Agrana | 10.85 | -0.91% | -23.05% |
| Amag | 24.40 | 2.09% | -8.61% |
| AT&S | 13.70 | 3.79% | -47.91% |
| Bawag | 77.20 | 2.93% | 60.90% |
| stock3 | 21.00 | 0.00% | 16.02% |
| CA Immo | 24.00 | 0.50% | -26.04% |
| DO&CO | 166.20 | 3.87% | 23.66% |
| Erste Group | 54.58 | 5.16% | 48.60% |
| FACC | 6.36 | 2.25% | 9.09% |
| Flughafen Wien | 53.20 | -0.75% | 4.52% |
| Frequentis | 27.40 | 10.04% | 0.37% |
| Immofinanz | 15.02 | -4.94% | -28.65% |
| Kapsch TrafficCom | 6.38 | -1.85% | -28.79% |
| Montana Aerospace | | | |
| Marinomed Biotech | 15.00 | 25.00% | -48.63% |
| Palfinger | 19.70 | 1.55% | -21.83% |
| Pierer Mobility | 11.10 | 16.84% | -77.67% |
| Porr | | | |

Dear active investors,

A good start for the Vienna Stock Market in the last month of the year, ATX TR gained 1,25 percent. News came from Agrana, Valneva, UBM, ReGuest, Valneva, Zumtobel, wienerberger and Marinomed.


BSN engine weekly Spitout: The **ATX TR** up 1,25% to 8,352,06 points this week. Year-to-date the ATX TR is now at **9,67%**. Up to now there were **135** days with a positive and **106** with a negative gain. From the year-high we are **4,07%** away, from the low **13,22%**. Statistically the best weekday so far 2024 is **Thursday** with 0,23%, the weakest is **Tuesday** with -0,19%.

These are the best-performers this week: **Pierer Mobility** 16,84% in front of Warimpex 15,38% and Frequentis 10,04%. And the following stocks performed worst: UBM -6,47% in front of Andritz -5,1% and Immofinanz -4,94%.

Further highlights this week: **Erste Group** for 7 days in a row up (6,98% gain from 51,02 to 54,58), also **Wienerberger** 4 days up (5,14% gain from 26,44 to 27,8), **Porr** 4 days up (11,01% gain from 15,8 to 17,54), **Bawag** 4 days up (4,68% gain from 73,75 to 77,2), **Uniq** 4 days up (1,54% gain from 7,15 to 7,26), **RBI** 4 days up (6,65% gain from 18,34 to 19,56), **UBM** 4 days down (8,62% loss from 17,4 to 15,9), **Pierer Mobility** 3 days down (9,02% loss from 12,2 to 11,1).

Best-performers year-to-date as of now: Bawag 60,9% (last year: -3,65 percent) followed by Erste Group 48,6% (last year: 22,84 percent) and Addiko Bank 45,69% (last year: 5,53 percent). And the worst-performing stocks year-to-date: Pierer Mobility -77,67% (Vorjahr: -26,59 percent), followed by AT&S -47,91% (Vorjahr: -17,81 percent) and Mayr-Melnhof -45,34% (Vorjahr: -16,27 percent).

High above the MA200: **Porr** 23,6%, **Bawag** 20,44% and **EuroTeleSites AG** 19%.
Down under the MA200: **Pierer Mobility** -63,21%, **Immofinanz** -33,67% and **Mayr-Melnhof** -31,71%.



Agrana: AGRANA Stärke GmbH, a subsidiary of AGRANA Beteiligungs-AG, has signed a joint venture agreement with starch producer INGREDION Germany GmbH for the joint further development of starch production in Romania. On the basis of the agreement, which is subject to the approval by the competent competition and regulatory authorities, INGREDION Germany GmbH will acquire 49% of the shares in S.C. AGFD Tândărei s.r.l. from AGRANA Stärke GmbH.

Agrana: weekly performance: **-0.91%**

| | | |
|-----------------------------|---------|---------|
| 17.54 | 8.81% | 38.11% |
| Österreichische Post | | |
| 28.60 | -0.69% | -12.54% |
| Polytec Group | | |
| 2.17 | -1.36% | -38.09% |
| RBI | | |
| 19.56 | 5.96% | 4.77% |
| RWT AG | | |
| 3.70 | 5.71% | -7.50% |
| Kontron | | |
| 17.46 | 2.11% | -18.87% |
| Semperit | | |
| 11.74 | 1.91% | -17.09% |
| S Immo | | |
| 22.20 | -0.45% | 77.60% |
| Sportradar Group | | |
| 16.10 | -1.23% | 62.38% |
| Strabag | | |
| 40.00 | 3.63% | -3.38% |
| Telekom Austria | | |
| 7.82 | -0.38% | 2.22% |
| UBM | | |
| 15.90 | -6.47% | -24.64% |
| Uniq | | |
| 7.26 | 0.83% | -2.68% |
| Varta AG | | |
| 1.94 | 1.15% | -90.64% |
| VAS AG | | |
| 6.00 | -20.00% | -32.58% |
| Verbund | | |
| 73.00 | -3.31% | -13.15% |
| VIG | | |
| 29.40 | 1.20% | 10.94% |
| Valneva | | |
| 1.93 | 4.61% | -59.11% |
| Wienerberger | | |
| 27.80 | 4.43% | -8.01% |
| Warimpex | | |
| 0.60 | 15.38% | -19.46% |
| Zumtobel | | |
| 4.95 | 3.56% | -21.18% |

TUESDAY

03

Valneva: Valneva SE, a specialty vaccine company, today reported positive antibody persistence data three years after vaccination with a single dose of its chikungunya vaccine IXCHIQ®. The results are in line with Valneva's expectations for this vaccine, confirming a strong and long-lasting antibody persistence across all age groups investigated. Among the 278 healthy adults still enrolled in the trial, 96% maintained neutralizing antibody titers well above the seroresponse threshold three years after the single-dose vaccination. Persistence of antibodies in older adults (age 65+) in terms of geometric mean titers (GMTs) and seroresponse rates (SRRs) was comparable to younger adults (18-64 years of age). Hence, the primary endpoint was met.

Valneva: weekly performance: 4.61%

UBM: UBM Development is selling a non-core asset in Poland for €17.85m to a polish entity – Rewa prosta spółka akcyjna (simple joint stock company) with its registered office in Cracow. The project Galeria Szperk is a shopping center with 57 well-known chains, national and local brands, including attractive retail and service outlets in Kosakowo (Gdynia), Poland. Thomas G. Winkler, CEO of UBM Development AG, explains: "Liquidity over profitability is UBM's mantra in 2024 and our transaction in Gdynia lives up to this approach."

UBM: weekly performance: -6.47%

WEDNESDAY

04

Request: ReGuest, a leading company in Customer Relationship Management (CRM) for hotels with a focus on guest communication located in Bozen, announced that an application for the inclusion of all 15.000.000 registered shares of the company in the Vienna MTF of the Vienna Stock Exchange, market segment "direct market plus", will be submitted to the Vienna Stock Exchange. If approved, all shares of the Company will be traded from Thursday, 12.12.2024. The Issuer's shares will be included in the auction trading procedure. The reference price of the shares was set at EUR 2,80 per share.

Valneva: Valneva SE, a specialty vaccine company, today announces the publication of an article on the global health and economic burden of mosquito-borne disease chikungunya in The British Medical Journal (BMJ), one of the world's leading peer-reviewed medical journals. The article, titled, "The Global Health and Economic Burden of Chikungunya from 2011 to 2020: A Model-Driven Analysis on the Impact of an Emerging Vector-Borne Disease," shows that chikungunya has a higher disease burden than was previously estimated, and costs related to the disease are substantial. According to the BMJ article, chikungunya could significantly impact local health systems due to its unpredictable and explosive nature.

Valneva: weekly performance: 4.61%

with
love
from
Vienna



Publisher: FC Chladek Drastil GmbH,
Czerninpl. 4, 1020 Wien · complete im-
print: boerse-social.com/impressum ·
editors: Christian Drastil ; Christine
Petzwinkler · bsngine:
Josef Chladek, Christian Drastil

subscription: boerse-social.com/21st

THURSDAY

05

wienerberger: Heimo Scheuch, CEO of wienerberger – a leading international provider of innovative, ecological solutions for the entire building envelope, in the fields of new build and renovation, as well as infrastructure in water and energy management – was appointed president of Cerame-Unie, the European Ceramic Industry Association, by decision of the Cerame-Unie Board of Presidents on April 29, 2024 ahead of the general assembly of Cerame-Unie scheduled December 4, 2024 in Brussels. He will take on this position starting January 1, 2025.

Wienerberger: weekly performance: [4.43%](#)

Zumtobel: Revenues recorded by lighting group Zumtobel in the first half of the current 2024/25 financial year rose by 0.6% to **577.6 mn Euro**. Revenues in the Components Segment continued to stabilise and increased by 3.4% to EUR 157.3 million. In the Lighting Segment, revenues increased by 0.4% to EUR 456.1 million. Operating results also improved slightly: After the first six months of the current financial year, the Zumtobel Group can report adjusted EBIT of EUR 41.2 million (H1 2023/24: EUR 40.0 million) and an adjusted EBIT margin of 7.1% (H1 2023/24: 7.0%). Net profit for the period totalled EUR 18.4 million (H1 2023/24: EUR 21.2 million). "In spite of these satisfactory results after the first half of this financial year, we remain cautious for good reason because the next six months will be challenging. This stems, above all, from the difficult geopolitical situation and the related uncertainties. Construction activity in Europe will decline somewhat stronger in this ongoing difficult economic environment, and competition on the market for professional lighting solutions is still intense." commented Alfred Felder, CEO of the Zumtobel Group.

Zumtobel: weekly performance: [3.56%](#)

FRIDAY

06

Marinomed: Marinomed Biotech announced that the Management Board has resolved to increase the Company's share capital again by issuing 83,750 new no-par value bearer shares against cash contributions. The new shares will be issued from the authorized capital 2024 under exclusion of statutory subscription rights of existing shareholders. All 83,750 new shares have been subscribed by a total of nine individually approached investors at these issue terms and conditions.

Marinomed Biotech: weekly performance: [25.00%](#)

THE NEXT 21st AUSTRIA WEEKLY WILL BE
ISSUED NEXT SATURDAY
HEAR OUR ENGLISH SPOKEN STOCK MARKET
PODCAST WITH ALLISON AND CHRIS EVERY
SUNDAY ON CHRISTIAN-DRASTIL.COM/
PODCAST

